title: ÐÐ°Ð¹Ð¿Ð»Ð°Ð¹Ð½ Ð¸Ð·ÑÑÐµÐ½Ð¸Ñ Ð²Ð°ÑÐ¸Ð°Ð±ÐµÐ»ÑÐ½Ð¾ÑÑÐ¸ ÑÐ¿Ð»Ð°Ð¹ÑÐ¸Ð½Ð³Ð° Ð¿ÑÐ¸ ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐºÐµ Ð»ÐµÐºÐ°ÑÑÑÐ²ÐµÐ½Ð½ÑÑ Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÐ¾Ð²
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¼Ð°Ð³Ð¸ÑÑÑÐ°
titleType: Subtitle
title: Streamlining differential-splicing analyses for drug discovery
Creators: name: ÐÐ¾ÑÐ¾ÑÐ½ÑÐ¹, ÐÐ¸ÐºÐ¸ÑÐ°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2021
Subjects: ÐÑÐ¾Ð³ÑÐ°Ð¼Ð¼Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ ÑÐ·ÑÐºÐ¸
ÐÑÑÐ¸ÑÐ»Ð¸ÑÐµÐ»ÑÐ½ÑÐµ Ð¼Ð°ÑÐ¸Ð½Ñ ÑÐ»ÐµÐºÑÑÐ¾Ð½Ð½ÑÐµ
ÐÐ½ÑÐ¾ÑÐ¼Ð°ÑÐ¸Ñ
Ð°Ð»ÑÑÐµÑÐ½Ð°ÑÐ¸Ð²Ð½ÑÐ¹ ÑÐ¿Ð»Ð°Ð¹ÑÐ¸Ð½Ð³
ÑÑÐ°ÑÐ¸ÑÑÐ¸ÑÐµÑÐºÐ¾Ðµ ÑÐµÑÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð¸Ðµ
alternative splicing
statistical testing

description: ÐÐ»ÑÑÐµÑÐ½Ð°ÑÐ¸Ð²Ð½ÑÐ¹ ÑÐ¿Ð»Ð°Ð¹ÑÐ¸Ð½Ð³ Ð²Ð¾Ð·Ð½Ð¸ÐºÐ°ÐµÑ Ð² Ð±Ð¾Ð»ÐµÐµ ÑÐµÐ¼ 90% Ð³ÐµÐ½Ð°Ñ ÑÐµÐ»Ð¾Ð²ÐµÐºÐ° Ð¸ Ð²Ð»Ð¸ÑÐµÑ Ð½Ð° ÑÐ°Ð·Ð²Ð¸ÑÐ¸Ðµ ÑÐ°Ð·Ð»Ð¸ÑÐ½ÑÑ Ð³ÐµÐ½ÐµÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ð¹. Ð¨Ð¸ÑÐ¾ÐºÐ¾ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·ÑÐµÐ¼Ð¾Ðµ Ð ÐÐ ÑÐµÐºÐ²ÐµÐ½Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ðµ ÐºÐ¾ÑÐ¾ÑÐºÐ¸Ð¼Ð¸ ÑÑÐ°Ð³Ð¼ÐµÐ½ÑÐ°Ð¼Ð¸ Ð½Ðµ Ð¿Ð¾Ð·Ð²Ð¾Ð»ÑÐµÑ ÑÐ²Ð½Ð¾ ÑÐ°ÑÐ¿Ð¾Ð·Ð½Ð°ÑÑ ÑÐ¾Ð±ÑÑÐ¸Ñ Ð°Ð»ÑÑÐµÑÐ½Ð°ÑÐ¸Ð²Ð½Ð¾Ð³Ð¾ ÑÐ¿Ð»Ð°Ð¹ÑÐ¸Ð½Ð³Ð°, ÑÐ°Ðº ÐºÐ°Ðº Ð´Ð°Ð½Ð½ÑÐµ ÑÑÐ°Ð½ÑÐºÑÐ¸Ð¿ÑÐ¾Ð² Ð¿Ð¾Ð»Ð½Ð¾Ð¹ Ð´Ð»Ð¸Ð½Ñ Ð½ÐµÐ´Ð¾ÑÑÑÐ¿Ð½Ñ. Ð­ÑÐ¾ Ð¿ÑÐ¸Ð²ÐµÐ»Ð¾ Ðº ÑÐ°Ð·Ð²Ð¸ÑÐ¸Ñ ÑÐ°Ð·Ð½Ð¾Ð¾Ð±ÑÐ°Ð·Ð¸Ñ Ð¿ÑÐ¾Ð³ÑÐ°Ð¼Ð¼Ð½ÑÑ Ð¼ÐµÑÐ¾Ð´Ð¾Ð² Ð´Ð»Ñ Ð¿ÑÐ¸Ð±Ð»Ð¸Ð¶ÐµÐ½Ð½Ð¾Ð³Ð¾ Ð°Ð½Ð°Ð»Ð¸Ð·Ð° Ð°Ð»ÑÑÐµÑÐ½Ð°ÑÐ¸Ð²Ð½Ð¾Ð³Ð¾ ÑÐ¿Ð»Ð°Ð¹ÑÐ¸Ð½Ð³Ð°. Ð Ð°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° ÑÐ¾Ð·Ð´Ð°Ð½Ð¸Ñ Ð¿Ð°Ð¹Ð¿Ð»Ð°Ð¹Ð½Ð° Ð¾Ð±ÑÐ°Ð±Ð¾ÑÐºÐ¸ Ð´Ð°Ð½Ð½ÑÑ Ð½Ð° ÑÐ·ÑÐºÐµ WDL Ð´Ð»Ñ Ð¿Ð¾Ð´ÑÑÐµÑÐ° Ð¸ ÑÑÐ°ÑÐ¸ÑÑÐ¸ÑÐµÑÐºÐ¾Ð³Ð¾ ÑÐµÑÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ ÑÑÑÐµÐºÑÐ¾Ð² ÑÐ¿Ð»Ð°Ð¹ÑÐ¸Ð½Ð³Ð° Ð² Ð³ÑÑÐ¿Ð¿Ð°Ñ Ð±Ð¸Ð¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¸Ñ Ð¾Ð±ÑÐ°Ð·ÑÐ¾Ð². ÐÐ°Ð¹Ð¿Ð»Ð°Ð¹Ð½ Ð°Ð´Ð°Ð¿ÑÐ¸ÑÐ¾Ð²Ð°Ð½ Ðº ÑÐ°Ð±Ð¾ÑÐµ Ñ Ð³ÐµÐ½Ð¾Ð¼Ð°Ð¼Ð¸ Ñ Ð½ÐµÐ¿Ð¾Ð»Ð½Ð¾Ð¹ Ð°Ð½Ð½Ð¾ÑÐ°ÑÐ¸ÐµÐ¹ Ð¸ Ð¿Ð¾Ð·Ð²Ð¾Ð»ÑÐµÑ Ð·Ð½Ð°ÑÐ¸ÑÐµÐ»ÑÐ½Ð¾ ÑÐ¿ÑÐ¾ÑÑÐ¸ÑÑ Ð°Ð²ÑÐ¾Ð¼Ð°ÑÐ¸ÑÐµÑÐºÑÑ Ð¿Ð°ÑÐ°Ð»Ð»ÐµÐ»ÑÐ½ÑÑ Ð¾Ð±ÑÐ°Ð±Ð¾ÑÐºÑ Ð±Ð¾Ð»ÑÑÐ¸Ñ ÑÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÐ¾Ð² Ð¸Ð½ÑÑÑÑÐ¼ÐµÐ½ÑÐ°Ð¼Ð¸ Ñ ÑÐ°Ð·Ð»Ð¸ÑÐ½ÑÐ¼Ð¸ Ð¿Ð¾Ð´ÑÐ¾Ð´Ð°Ð¼Ð¸. Ð ÑÐ°Ð±Ð¾ÑÐµ Ð¸ÑÑÐ»ÐµÐ´ÑÑÑÑÑ Ð¾ÑÐ¾Ð±ÐµÐ½Ð½Ð¾ÑÑÐ¸ Ð¸ ÑÐ¾ÑÐ½Ð¾ÑÑÑ Ð²ÐºÐ»ÑÑÐµÐ½Ð½ÑÑ Ð¸Ð½ÑÑÑÑÐ¼ÐµÐ½ÑÐ¾Ð², Ð¾Ð±ÑÐ¸Ðµ ÑÐ°ÑÐ°ÐºÑÐµÑÐ¸ÑÑÐ¸ÐºÐ¸ Ð¿ÑÐ¾Ð¸Ð·Ð²Ð¾Ð´Ð¸ÑÐµÐ»ÑÐ½Ð¾ÑÑÐ¸ Ð¿Ð°Ð¹Ð¿Ð»Ð°Ð¹Ð½Ð°. Ð Ð°Ð±Ð¾ÑÐ° Ð´ÐµÐ¼Ð¾Ð½ÑÑÑÐ¸ÑÑÐµÑ ÑÐ½Ð¸Ð²ÐµÑÑÐ°Ð»ÑÐ½Ð¾ÑÑÑ ÑÐµÑÐµÐ½Ð¸Ñ Ð¸ Ð¿Ð¾ÑÐµÐ½ÑÐ¸Ð°Ð»ÑÐ½ÑÐµ Ð¿ÐµÑÑÐ¿ÐµÐºÑÐ¸Ð²Ñ Ð´Ð»Ñ ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐºÐ¸ Ð»ÐµÐºÐ°ÑÑÑÐ² Ð½Ð° Ð°Ð½Ð°Ð»Ð¸Ð·Ðµ 3Ñ Ð¾Ð±ÑÐµÐ´Ð¾ÑÑÑÐ¿Ð½ÑÑ ÑÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÐ¾Ð². ÐÑÐ¾Ð¼Ðµ ÑÐ¾Ð³Ð¾, Ð¾Ð¿Ð¸ÑÑÐ²Ð°ÐµÑÑÑ ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐ°Ð½Ð½Ð¾Ðµ Ð´Ð»Ñ Ð²Ð¸Ð·ÑÐ°Ð»Ð¸Ð·Ð°ÑÐ¸Ð¸ ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐ¾Ð² Ð¿ÑÐ¸Ð»Ð¾Ð¶ÐµÐ½Ð¸Ðµ Shiny app.
description: Alternative splicing occurs in more than 90% of human genes and reported to influence various diseases. Commonly used short-read RNA-sequencing does not allow explicitly identify splicing events because full-length transcript data is not available. To overcome that, different approaches of alternative splicing analysis were developed. We present a WDL language pipeline based on published tools to quantify and test for differences in splicing between bulk RNA-seq sample groups. The pipeline is constructed to work well with no well-annotated genomes and to facilitate unsupervised processing of huge experiments by tools of different approaches. We evaluate features and precision of these tools and overall performance of the pipeline, we demonstrate versatility and possible outcome for drug discovery process by analyzing 3 public experiments. Additionally, we describe a developed Shiny application that is designed to gather insights from the pipeline outcomes.